Saturday 17 October 2026 Export SXTC’s income statement to Excel — free account

China SXT Pharmaceuticals, Inc.

SXTC Healthcare Drug Manufacturers Specialty & Generic

China SXT Pharmaceuticals, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 million, down 34.6% from fiscal 2025.

0.07 0.00 0.00%

Follow SXTC

Alert me

Market cap: $710.0K
P/E: 0.0×
Fwd P/E: −1.0×
Dividend yield: —
F-score: 3/9
Altman Z: −0.84
Beneish M: −2.12
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 78.70%

Capital & Financial Ratios $m

Market Cap 0.71

Revenue 4.57

Net Income (16.68)

Free Cash Flow (9.37)

Net Debt (27.18)

Current Ratio 7.94

Debt/Equity 0.03

P/E ratio 0.00

Fwd P/E (1.02)

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth (45.58%)

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

EV/FCF against its own 10 years 50.45%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2016	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	2026
Cash	17	12	18	28
Receivables	1	1	2	3
Inventory	1	1	1	1
Other	0	0	0	2
	20	14	21	35

	2023	2024	2025	2026
Payables	1	1	1	0
ST’ Debt	3	2	1	0
Other	0	0	0	0
	14	9	6	4

Compound Annual Growth %

	10y	5y	3y
Sales	(11.17%)	(24.94%)	(16.74%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	44.61%	13.23%	26.45%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’26	—	—	—	—	1
’25	—	—	—	—	2
’24	—	—	—	—	2
’23	—	—	—	—	2
’22	—	—	—	—	3
’21	—	—	—	—	5

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’26	—	—	—	—	(4)
’25	—	—	—	—	(2)
’24	—	—	—	—	(2)
’23	—	—	—	—	0
’22	—	—	—	—	0
’21	—	—	—	—	(1)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’26	(4)	—	(2)	—	(4)
’25	(2)	—	(1)	—	(2)
’24	(2)	—	(1)	—	(2)
’23	0	—	(1)	—	0
’22	0	—	0	—	0
’21	(1)	—	0	—	(1)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’26	—	—	—	—	(730.40)
’25	—	—	—	—	(27.70k)
’24	—	—	—	—	(341.01k)
’23	—	—	—	—	(2.13m)
’22	—	—	—	—	(5.52)
’21	—	—	—	—	(3.82)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	—	—	780,000.00	266,400.00	151,500.00	27,000.00	19,812.00	3,600.00	3,732.00	0.06	Analyst estimates 2027–2029 Powerpack
	High	—	—	28,020,000.00	1,776,000.00	1,536,000.00	684,000.00	204,000.00	40,440.00	68,376.00	83,760.00
People
People	Employees	—	105	96	97	96	87	78	75	75	56
	Revenue/emp, $m	0.00	0.07	0.07	0.05	0.05	0.03	0.03	0.03	0.02	0.02
Income, $m
Income, $m	Revenue	5	7	7	5	5	3	2	2	2	1
	Gross margin, %	47.36	48.46	65.77	52.37	59.44	48.10	21.62	28.73	21.10	21.85
	EBT	2	2	2	(10)	(3)	(5)	(6)	(3)	(3)	(6)
	EBT margin, %	32.37	23.19	25.55	(201.26)	(61.56)	(207.81)	(301.00)	(160.67)	(189.77)	(545.22)
	Net income	1	1	2	(10)	(3)	(6)	(6)	(3)	(3)	(6)
	Depreciation	0	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	0.24	0.35	0.34	0.84	6.64	2.50	0.00	0.00	17,409.00	133.89
	Earnings	0.06	0.06	0.07	(1.66)	(3.82)	(5.52)	(2,125,373.00)	(341,014.90)	(27,701.49)	(730.40)
	Cash flow	0.01	0.10	0.01	0.15	(1.83)	0.26	0.00	0.00	(23,453.00)	(472.65)
	Capex	(0.01)	(0.05)	(0.03)	(0.07)	(0.13)	(0.06)	0.00	0.00	635.00	0.00
	Free cash flow	0.01	0.04	(0.02)	0.09	(1.96)	0.20	0.00	0.00	(22,818.00)	(472.65)
	Book value	0.09	0.16	0.54	1.52	22.18	15.79	0.00	0.00	154,398.00	3,494.99
	Shares, m	20	20	21	6	1	1	0	0	0	0
Valuation, ×
Valuation, ×	P/E	143.50	143.50	101.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	EV/Sales	0.00	0.00	0.00	(0.05)	(1.34)	(1.83)	(3.04)	(2.11)	(3.79)	(5.94)
	EV/FCF	0.00	0.00	(3.72)	0.18	3.73	6.79	16.41	2.93	2.80	2.90
Cash, $m
Cash, $m	Operating cash flow	0	2	0	1	(1)	0	0	(2)	(2)	(4)
	Capex	0	(1)	(1)	0	0	0	0	0	0	—
	Free cash flow	0	1	0	1	(1)	0	0	(2)	(2)	(4)
Balance, $m
Balance, $m	Working capital	1	2	9	7	5	5	5	5	15	30
	Total debt	0	0	0	7	0	2	3	2	1	1
	Net debt	0	0	(9)	(1)	(13)	(14)	(14)	(10)	(17)	(27)
	Shareholders’ equity	2	3	11	9	16	16	15	14	15	30
Returns, %
Returns, %	ROA	20.21	18.15	12.25	(52.53)	(9.77)	(16.85)	(18.81)	(11.76)	(14.75)	(22.00)
	ROIC	47.93	33.86	58.66	(9.48)	(51.90)	(111.79)	(453.09)	(36.86)	0.00	(175.91)
	ROE	91.32	46.22	21.39	(100.32)	(21.67)	(35.42)	(38.15)	(21.65)	(22.50)	(27.49)

Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jan 0001

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
AKAN Akanda Corp.	$3.5M	—	—	—	—	−472.01% (below 0%: shrinking)	(197.87%)	0.00%	Compare
PRFX PainReform Ltd.	$2.6M	— (loss-making)	— (loss-making)	—	n/m	+52.56% (above 0%: growing)	0.00%	0.00%	Compare
BTAIQ BioXcel Therapeutics, Inc.	$2.3M	— (loss-making)	— (loss-making)	+51.67% (above 0%: growing)	n/m	+51.51% (above 0%: growing)	87.91%	(5,600.55%)	Compare
IMCC IM Cannabis Corp.	$2.2M	— (loss-making)	— (loss-making)	−40.28% (below 0%: shrinking)	n/m	−266.81% (below 0%: shrinking)	19.83%	(27.54%)	Compare
NEPTF Neptune Wellness Solutions Inc.	$1.6M	— (loss-making)	— (loss-making)	−37.75% (below 0%: shrinking)	n/m	+53.44% (above 0%: growing)	13.62%	(232.88%)	Compare
PTPI Petros Pharmaceuticals, Inc.	$1.0M	— (loss-making)	— (loss-making)	+1,070.55% (above 0%: growing)	n/m	+71.27% (above 0%: growing)	73.82%	0.00%	Compare
SBFM Sunshine Biopharma, Inc.	$990.0K	— (loss-making)	— (loss-making)	−1.56% (below 0%: shrinking)	n/m	+49.38% (above 0%: growing)	26.20%	(17.41%)	Compare
LSDIF Lucy Scientific Discovery Inc.	$900.0K	— (loss-making)	—	—	n/m	−493.98% (below 0%: shrinking)	59.79%	(8,891.75%)	Compare
SXTC China SXT Pharmaceuticals, Inc.	$710.0K	— (loss-making)	— (loss-making)	−16.76% (below 0%: shrinking)	+92.67% (above 0%: growing)	−107.59% (below 0%: shrinking)	44.09%	0.00%
Median of peers	$1.9M	—	—	−1.56%	—	+50.45%	23.02%	(22.47%)

All 86 Drug Manufacturers Specialty & Generic stocks →

China SXT Pharmaceuticals, Inc. (SXTC) key facts

Concern: China SXT Pharmaceuticals, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 million, down 34.6% from fiscal 2025.
China SXT Pharmaceuticals, Inc. (SXTC) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, SXTC traded at $0.07, a market capitalization of $710,000.00.
Return on equity was −27.5% and debt-to-equity 0.03.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −0.84 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.